Stargardt Disease Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Stargardt Disease Therapeutics Market is segmented By Drug Type (LBS-008, Emixustat), By Age Group (Children (Below 17 Years), Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Stargardt Disease Therapeutics Market Overview

The Global Stargardt Disease Therapeutics Market reached USD 197.1 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1,385.6 million by 2030. The global Stargardt Disease Therapeutics market is expected to exhibit a CAGR of 28.8% during the forecast period (2023-2030). Therapeutics for the management and possibly slowing of the progression of Stargardt disease, a genetic retinal illness that damages the macula and causes loss of central vision, are referred to as Stargardt disease.

While there is presently no treatment for Stargardt disease, there are a number of therapeutic options being investigated.

Stargardt Disease Therapeutics Market Scope

To know more insights – Download Sample

Stargardt Disease Therapeutics Market Dynamics

Increasing Research Activities Are Driving The Global Stargardt Disease Therapeutics Market Growth.

Targeting particular processes implicated in the course of Stargardt disease is being researched using a variety of pharmacological drugs. These treatments are intended to lessen inflammation and oxidative stress as well as decrease the buildup of harmful metabolites in the retina. For instance, as of 2023, teenagers with Stargardt disease (ages 12 to 18) are being enrolled by the San Diego-based biopharmaceutical company Belite Bio in DRAGON, a Phase 3 clinical trial for the newly released oral drug Tinlarebant, which is intended to halt the disease's progression and vision loss. 

Tinlarebant is made to inhibit retinol-binding protein 4 (RBP4), which lowers vitamin A uptake into the retina and lessens the synthesis and buildup of toxic vitamin A metabolites, which are a defining feature of Stargardt disease. 

The Development Of Gene Therapy for Stargardt Disease Is Driving The Global Stargardt Disease Therapeutics Market Growth. 

Researchers discovered the first concrete proof that Stargardt-related ABCA4 gene mutations damage a layer of cells in the eye known as the retinal pigment epithelium (RPE) using a new stem-cell-based model built from skin cells. The finding provides a therapeutic approach for the disease, which at the moment has no known cure, and sheds light on how Stargardt disease develops. 

The National Eye Institute (NEI), a division of the National Institutes of Health, was the site of the study. By creating patient-derived RPE devoid of ABCA4, also known as an ABCA4 knockout, using the gene-editing technique CRISPR/Cas9, they were able to investigate the role of ABCA4 in retinal pigment epithelium development. They discovered that the maturation of the patient-derived retinal pigment epithelium was unaffected by the absence of ABCA4.   

The Lack Of Skilled Professionals Is Hampering the global Stargardt disease Therapeutics Market Growth.

The shortage of qualified workers is a problem that many different industries and sectors encounter. It alludes to the dearth of people who have the training, experience, and skill required to carry out particular duties or positions successfully. Rapid technology improvements, changing employment needs, inadequate training programs, and demographic changes are only a few of the causes of this shortage. 

Stargardt Disease Therapeutics Market Segment Analysis

The global Stargardt disease therapeutics market is segmented based on drug type, age group, distribution channel, and region.

The Children Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.

The chikdren segment accounted for the highest market stake accounting for approximately 58.5% of the Stargardt disease therapeutics market in 2022. Stargardt disease often develops in childhood or adolescence, which can have a substantial effect on children. Between the ages of 6 and 20, Stargardt disease is commonly diagnosed in childhood or adolescence. The disorder is characterized by a progressive loss of central vision, which can impair a child's capacity for skills that call for acute central vision, such as reading, face recognition, and performing other tasks. 

For instance, in June 2023, Gildeuretinol (ALK-001), a drug developed by Alkeus Pharmaceuticals to treat Stargardt disease, a genetic cause of blindness in children and young adults, received $150 million in Series B financing to pursue its registration and commercialization.

Source: DataM Intelligence Analysis (2023)

Stargardt Disease Therapeutics Market Geographical Penetration

North America Holds A Dominant Position In The Global Stargardt Disease Therapeutics Market.

North America is estimated to hold around 42.7% of the total market share throughout the forecast period. Active market players and rising research activities boost regional growth over the forecast period. Stargardt illness is a serious genetic condition that damages children's and adults' central vision and frequently results in blindness. 

There are no approved therapeutic alternatives at the moment. Weill Cornell Medicine in New York City conducted significant discovery research that served as the foundation for REV-0100. Pre-clinical tests revealed that REV-0100 can lower increased levels of the hazardous lipid substance lipofuscin. Thus, reVision is prepared to show how lowering lipofuscin levels can affect how Stargardt’s disease progresses.

Source: DataM Intelligence Analysis (2023)

Stargardt Disease Therapeutics Market Players

The major global players in the market include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., and F. Hoffmann-La Roche AG among others.

COVID-19 Impact on Stargardt Disease Therapeutics Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine war may affect the Stargardt disease therapeutics market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. The economies of Russia and Ukraine have both suffered as a result of the conflict. Economic sanctions, strained trade ties, deteriorated infrastructure, and investor apprehension have all contributed to the region's economic downfall.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the Stargardt disease therapeutics market to improve various aspects of the customer experience. The accuracy and effectiveness of diagnosing Stargardt disease can be enhanced with AI analysis. AI systems can identify early indicators of the disease and distinguish them from other retinal disorders by examining medical imaging data, such as retinal scans. Additionally, based on a variety of clinical and genetic parameters, AI models can help in forecasting disease progression and assessing patient prognosis.

By Drug Type 

• LBS-008
• Emixustat 

By Age Group 

• Children 
• Adult  

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies 

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In January 2023, Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, reported that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of Stargardt disease to improve visual function.

Why Purchase the Report?

• To visualize the global Stargardt disease therapeutics market segmentation based on the product, material, distribution channel, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Stargardt disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Stargardt disease therapeutics market report would provide approximately 61 tables, 55 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Pharmaceuticals related reports, please click here